Pricing Log in Create free account

Janux Therapeutics, Inc. (JANX) vs Nuvectis Pharma, Inc. (NVCT)

Janux Therapeutics, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Janux Therapeutics, Inc. and Nuvectis Pharma, Inc. are of similar size ($758.1M and $722.2M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −300.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Nuvectis Pharma, Inc. leads on 7 and Janux Therapeutics, Inc. on 4.

Valuation

Metric JANX NVCT Biotechnology median
P/E n/m n/m 11.58
P/S 23.60 n/m 9.61
P/B 0.86 4.90 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA 1.07 n/m 0.72
EV/Sales (4.81) n/m 9.43
Earnings yield (12.77%) (8.97%) (32.28%)
Free cash flow yield (6.90%) (6.49%) (22.27%)

Profitability

Metric JANX NVCT Biotechnology median
Gross margin 100.00% — 68.81%
Operating margin (419.24%) 0.00% 0.00%
Net margin (299.95%) 0.00% 0.00%
Free cash flow margin (162.70%) 0.00% 0.00%
Return on equity (10.58%) (66.98%) (50.30%)
Return on assets (9.94%) (57.20%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric JANX NVCT Biotechnology median
Revenue growth (TTM) 214.40% — 6.78%
EPS growth (last fiscal year) (42.97%) (18.92%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric JANX NVCT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 17.69 9.92 4.74
Net debt to EBITDA 5.58 1.15 1.01

Dividend

Metric JANX NVCT Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric JANX NVCT Biotechnology median
Market cap 758.06m 722.17m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack